drugset

drugset / Trial / NCT04532203

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

NCT04532203 ↗

Phase 0 Recruiting 72 enrolled Zhejiang University

NaSingle-groupOpen-labelTreatment

Summary

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Timeline

Start: 2020-11-01
Primary completion: 2023-11-01
Completion: 2026-11-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAR-T cells	Cell therapy	—	Intravenous

Indications